RVMD Stock Summary and Trading Ideas (Revolution Medicines | NASDAQ:RVMD)

Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.

Revolution Medicines trades on the NASDAQ stock market under the symbol RVMD.

As of February 5, 2026, RVMD stock price declined to $96.15 with 1,780,314 million shares trading.

RVMD has a beta of 1.23, meaning it tends to be more sensitive to market movements. RVMD has a correlation of 0.13 to the broad based SPY ETF.

RVMD has a market cap of $18.59 billion. This is considered a Large Cap stock.

Last quarter Revolution Medicines reported $0 in Revenue and -$1.61 earnings per share. This fell short of revenue expectation by $-6 million and missed earnings estimates by -$.21.

In the last 3 years, RVMD traded as high as $124.49 and as low as $15.44.

The top ETF exchange traded funds that RVMD belongs to (by Net Assets): VTI, VB, VBK, VXF, XBI.

RVMD has outperformed the market in the last year with a return of +127.2%, while the SPY ETF gained +13.4%. In the last 3 month period, RVMD beat the market returning +64.2%, while SPY returned +0.3%. However, in the most recent 2 weeks RVMD has underperformed the stock market by returning -18.2%, while SPY returned -1.6%.

RVMD support price is $93.03 and resistance is $99.99 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RVMD shares will trade within this expected range on the day.